Use of Paclitaxel to Successfully Treat Children, Adolescents, and Young Adults with Kaposi Sarcoma in Southwestern Tanzania

Treating Kaposi sarcoma (KS) in children, adolescents, and young adults (AYA) remains a challenge in low- and middle-income countries (LMIC) where chemotherapy options and availability are limited. We describe a retrospective cohort review of pediatric patients with KS treated with paclitaxel in Mbe...

Full description

Saved in:
Bibliographic Details
Published in:Children (Basel) 2021-04, Vol.8 (4), p.275
Main Authors: Adinani, Hamidu, Campbell, Liane, El-Mallawany, Nader Kim, Slone, Jeremy, Mehta, Parth, Bacha, Jason
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
AIDS
Chemotherapy
Childrens health
Classification
Clinical outcomes
Edema
Global health
HIV
HIV-related malignancy
HIV/AIDS
Human immunodeficiency virus
Kaposi sarcoma
Kaposis sarcoma
Oral diseases
Pediatrics
Quality of life
Teenagers
Young adults
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treating Kaposi sarcoma (KS) in children, adolescents, and young adults (AYA) remains a challenge in low- and middle-income countries (LMIC) where chemotherapy options and availability are limited. We describe a retrospective cohort review of pediatric patients with KS treated with paclitaxel in Mbeya, Tanzania, between 1 March 2011 and 31 December 2019. Paclitaxel was given to patients who had KS relapse, a contraindication to bleomycin, vincristine, and doxorubicin (ABV), special circumstances in which a clinician determined that paclitaxel was preferable to ABV, or experienced treatment failure, defined as persistent KS symptoms at the completion of treatment. All patients also received multidisciplinary palliative care. Seventeen patients aged 5.1-21.3 years received paclitaxel, of whom 47.1% (8/17) had treatment failure, 29.4% (5/17) received paclitaxel as initial treatment, and 23.5% (4/17) had relapsed. All HIV positive patients (16/17) were given anti-retroviral therapy (ART) and 87.5% (14/16) achieved viral load
ISSN:2227-9067
2227-9067
DOI:10.3390/children8040275